Given their inherent memory and sustained anti-tumor attributes, therapeutic interventions, such as adoptive T-cell therapy and anti-PD-1 therapy targeting TTSM cells, may represent an emergent focal point in the realm of cancer immunotherapy research and clinical applications. The gene discussed is PDCD1; the disease is neoplasm.